Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma

Area of Science:

• Oncology
• Biochemistry
• Molecular Biology

Background:

• MYC-driven medulloblastoma (MB) is a highly aggressive pediatric brain tumor.
• Therapy resistance and frequent recurrence are hallmarks of this aggressive cancer.
• Identifying novel therapeutic targets is crucial for improving patient outcomes.

Purpose of the Study:

• To identify and validate cancer-selective metabolic vulnerabilities in MYC-driven MB.
• To investigate the therapeutic potential of targeting dihydroorotate dehydrogenase (DHODH) in MB.
• To elucidate the molecular mechanisms underlying DHODH inhibition in MB.

Main Methods:

• Integrated unbiased genetic screening and metabolomic profiling of MB cells.
• Utilized small-molecule inhibitors targeting DHODH.
• Assessed therapeutic efficacy in patient-derived MB xenografts in vivo.
• Analyzed downstream effects of DHODH inhibition on cellular metabolism and signaling pathways.

Main Results:

• Identified DHODH, crucial for pyrimidine biosynthesis, as a key metabolic vulnerability.
• DHODH inhibition led to pyrimidine starvation, reduced O-GlcNAcylation, and c-Myc degradation.
• Observed cell-cycle arrest and apoptosis in MB cells upon DHODH inhibition.
• An orally available DHODH inhibitor demonstrated significant efficacy in preclinical MB models.

Conclusions:

• Targeting DHODH represents a promising therapeutic strategy for MYC-driven medulloblastoma.
• DHODH inhibition offers a selective approach with potential for reduced neurotoxicity.
• Reprogramming pyrimidine metabolism opens new avenues for pediatric brain tumor treatment.